This study compared the in vitro activities of ertapenem, ceftriaxone, co-amoxiclav, ciprofloxacin and piperacillin-tazobactam against 314 aerobic bacteria and of ertapenem, piperacillin-tazobactam, cefoxitin, ceftriaxone, chloramphenicol, ticarcillin-clavulanate, ampicillin-sulbactam, clindamycin and metronidazole against 500 anaerobic bacteria from 212 patients with acute pelvic infection. Antimicrobial susceptibilities were determined by broth microdilution (aerobes) or agar dilution (anaerobes), following NCCLS guidelines. The most common isolates were Enterobacteriaceae and Peptostreptococcus spp. Ertapenem was the most active drug tested against Enterobacteriaceae (100% susceptible) and anaerobes (99.8% susceptible); the least active agents were co-amoxiclav (79% of Enterobacteriaceae susceptible) and ceftriaxone (85.9% of anaerobes susceptible). All agents tested had excellent activity against β-haemolytic streptococci and methicillin-susceptible Staphylococcus aureus.
Introduction
Ertapenem (formerly MK-0826, Merck & Co.) is a once-aday parenteral β-lactam antimicrobial agent licensed in the USA in November 2001 and in Europe in May 2002. This structurally unique carbapenem has a focused spectrum of activity in that it is highly active against many Gram-positive and Gram-negative aerobic, facultative and anaerobic bacteria that are generally associated with community-acquired infections but has minimal activity against Pseudomonas aeruginosa, Acinetobacter spp. and enterococci, 1,2 which are more often associated with nosocomial infection. Given this spectrum of activity, a large double-blind clinical trial was conducted to assess the efficacy of ertapenem in the treatment of moderate to severe acute pelvic infection. 3 These infections typically contain a mixture of aerobic and anaerobic bacteria against which ertapenem is highly active in vitro.
The objectives of this study were to assess the in vitro activity of ertapenem against aerobic and anaerobic bacterial pathogens isolated from patients with acute pelvic infection enrolled in the clinical trial and to compare the activity of ertapenem with agents that may be used to treat acute pelvic infection as single-agent or combination therapy.
Materials and methods
Aerobic and anaerobic bacteria isolated from a specimen from the site of pelvic infection collected at surgery or with a protected sampling device or from the bloodstream of patients with acute pelvic infection were identified using standard procedures. 4, 5 Isolates of aerobic bacteria were shipped to Merck Research Laboratories (Rahway, NJ, USA) on trypticase soy or chocolate agar slants at room temperature or were frozen at -70°C and shipped on dry ice. For anaerobic culture, specimens of pus or tissue were placed in anaerobic transport tubes (Anaerobe Systems, Morgan Hill, CA, USA) and sent via express delivery services to the R. M. Alden Research Laboratory (Santa Monica, CA, USA), where they were processed in an anaerobic chamber, plated on selective and nonselective anaerobic agar media and incubated at 35°C in the anaerobic chamber for at least 5 days before examination. After identification, aerobes were stored in 15% skimmed Sorensen's phosphate buffer, pH 7, at ∼1.0 mg base/mL. Stock solutions were filter-sterilized and diluted in the appropriate medium. For testing anaerobes, antimicrobial agents were reconstituted according to the manufacturers' directions. Serial two-fold dilutions of various concentrations of the drugs were prepared on the day of testing and added to supplemented (as above) brucella agar. Ampicillinsulbactam was in a fixed ratio of 2:1; ticarcillin was serially diluted and combined with clavulanate, tested at a constant concentration of 2 mg/L; and piperacillin was serially diluted and combined with tazobactam, which was tested at a constant concentration of 4 mg/L.
Antimicrobial susceptibility of aerobic bacteria was evaluated by broth microdilution, using microtitre trays prepared in-house, according to NCCLS guidelines. 6 Trays were inoculated using a Dynatech MIC-2000 Inoculator (Dynex Technologies, Chantilly, VA, USA). To ensure an appropriate inoculum density, bacterial concentrations in the growth control wells of randomly selected isolates were assayed. Anaerobes were tested by agar dilution according to NCCLS guidelines. 7 Supplemented brucella agar plates were prepared with dilutions of each of the test antimicrobial agents and inoculated with 10 5 colony forming units per spot, using a Steers replicator (Craft Machine, Chester, PA, USA), and incubated in an anaerobic chamber at 37°C for 44 h. The MIC was defined as the lowest concentration of an agent that yielded no growth or a marked reduction in growth compared with the growth control. When testing aerobic and anaerobic bacteria, standard quality control strains were included with each test run.
Interpretive MIC breakpoints (in mg/L) for ertapenem are ≤2 for susceptible, 4 for intermediate and ≥8 for resistant for Enterobacteriaceae and staphylococci; and ≤4 for susceptible, 8 for intermediate and ≥16 for resistant for anaerobes. For β-haemolytic streptococci, the breakpoint for susceptible is ≤1 mg/L. There are no proposed breakpoints for ertapenem against enterococci, as there are none defined for other carbapenems, or non-fermentative Gram-negative bacilli, because the drug is not indicated for treatment of infections caused by these organisms.
Results and discussion
After excluding duplicate isolates, 814 bacteria [314 (38.6%) aerobes, 500 (61.4%) anaerobes] from 212 patients enrolled at centres in the USA, Latin America, Europe, Russia and South Africa were included in this study. Enterobacteriaceae comprised 48.1% (151/314) of the aerobic bacteria (18.6% of all isolates). The most common single aerobe was Escherichia coli, which accounted for 28.7% of the aerobic bacteria (59.6% of the Enterobacteriaceae). Non-fermentative Gramnegative bacilli were encountered infrequently (3.8% of the aerobes, 1.5% of all isolates). Of the anaerobes, although 280 (56.0%) were Gram-negative organisms, the genus isolated most often was Peptostreptococcus (169 isolates, 33.8% of all anaerobes). Bacteroides spp. comprised 17.4% of all anaerobes (87 isolates). Peptostreptococcus anaerobius, Prevotella bivia and Peptostreptococcus asaccharolyticus were the most commonly encountered species of anaerobes.
The antimicrobial activities of ertapenem and comparator agents against the aerobic and anaerobic bacteria tested are summarized in Tables 1 and 2 , respectively. Ertapenem was the most active agent against Enterobacteriaceae and had the most potent activity, based on values for inhibition of 50% (MIC 50 ) and 90% (MIC 90 ) of the isolates. All isolates of Enterobacteriaceae were susceptible to ertapenem, compared with 99% for ciprofloxacin and ceftriaxone, 87% for piperacillin-tazobactam and 79% for co-amoxiclav. All antimicrobials had excellent activity against streptococci and methicillin-susceptible Staphylococcus aureus (MSSA). Ertapenem had the most potent activity against MSSA on a per-weight basis. As expected, ertapenem, ceftriaxone and co-amoxiclav had minimal activity against P. aeruginosa, as did ertapenem and ceftriaxone against enterococci.
Ertapenem, piperacillin-tazobactam, chloramphenicol and ampicillin-sulbactam were most active against anaerobes: respectively, 99.8%, 99.6%, 99.4% and 98.8% of all anaerobes were susceptible to these agents. The acute pelvic infections in this clinical trial were usually polymicrobial, with causal pathogens representing the normal vaginal flora: Streptococcus agalactiae, E. coli, peptostreptococci, Prevotella spp. and Bacteroides spp., as has been reported by others. [8] [9] [10] In this in vitro study, ertapenem was the most active of the agents evaluated against the broad array of pathogens isolated. As anticipated, ertapenem had minimal activity against the unusual isolates of non- fermentative Gram-negative bacilli and the more frequently encountered enterococci. However, although commonly isolated in polymicrobial acute pelvic infections, enterococci are generally considered of low pathogenicity compared with other pyogenic organisms in mixed infections. 11 In the present clinical trial, all patients with acute pelvic infection whose cultures grew enterococci and who were treated with ertapenem were cured, thus substantiating the lack of virulence of enterococci in these infections. 3 In summary, ertapenem was highly active in vitro against many aerobic and anaerobic bacterial pathogens recovered from patients with acute pelvic infection. Ertapenem was more active than piperacillin-tazobactam, ceftriaxone, ciprofloxacin and co-amoxiclav against Enterobacteriaceae and more active than piperacillin-tazobactam, ceftriaxone, ticarcillin-clavulanate, ampicillin-sulbactam, metronidazole, cefoxitin, clindamycin and chloramphenicol against anaerobes, which were the most frequent pathogens.
